Genzyme Sues Over Endo's Bid To Sell Generic Renvela

By Erin Marie Daly · April 27, 2011, 8:24 PM EDT

Genzyme Corp. on Wednesday filed suit in Maryland accusing Endo Pharmaceuticals Inc. of infringing its patent covering Renvela by seeking approval to sell a generic version of the kidney disease treatment...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Genzyme Corporation v. Endo Pharmaceuticals Inc.

Case Number

Court

Maryland

Nature of Suit

Patent

Date Filed

April 27, 2011

Recent Articles By Erin

May 19, 2011
Genentech Sues Apotex Over Generic Valcyte
May 19, 2011
CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
May 18, 2011
Firms, Experts Allowed To Stay In AndroGel MDL
May 10, 2011
Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
May 03, 2011
2nd Circ. Rejects Nurses Review Of Class Cert. Denial
April 27, 2011
Asahi, Actelion Throw Final Punches In Fasudil IP Row
April 20, 2011
Novartis Targets Teva Over Myfortic Patents
April 13, 2011
HGS Fires Round 2 At Genentech Over Lupus Drug IP
April 13, 2011
MetroPlus, HHC Evade State Claims In OT Action
April 08, 2011
UK Court Shutters Merck's Cosopt Patent Fight